Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology Changes Name to OncoPlex Diagnostics, Plans 2012 Launch of Lung Cancer Test

Premium

Clinical proteomics firm Expression Pathology has changed its name to OncoPlex Diagnostics and opened a CLIA laboratory in Rockville, Md.

The company announced last week that by the end of the year it plans to launch a test, run out of its new CLIA facility, for distinguishing adenocarcinoma from squamous cell carcinoma in lung cancer patients.

The test will use formalin-fixed paraffin embedded tissue, making it, according to OncoPlex, the first clinical proteomics test for cancer to do so. The company also said that it plans to introduce additional tests in 2013, including a multiplex breast cancer assay.

OncoPlex uses selected-reaction monitoring mass spec combined with proprietary technology for solubilizing peptides and proteins in FFPE tissue, enabling detection and quantitation of proteins from this widely used sample source.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.